Zoetis Inc. (ZTS)
USD 167.01
(-2.21%)
USD 167.01
(-2.21%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 4.76 Billion USD | 5.52% |
| 2022 | 4.51 Billion USD | 38.39% |
| 2021 | 3.26 Billion USD | -13.27% |
| 2020 | 3.76 Billion USD | -19.64% |
| 2019 | 4.67 Billion USD | -3.53% |
| 2018 | 4.85 Billion USD | 43.11% |
| 2017 | 3.38 Billion USD | -9.41% |
| 2016 | 3.74 Billion USD | 0.73% |
| 2015 | 3.71 Billion USD | 34.18% |
| 2014 | 2.76 Billion USD | -9.16% |
| 2013 | 3.04 Billion USD | 1049.81% |
| 2012 | 265 Million USD | -46.57% |
| 2011 | 496 Million USD | -23.46% |
| 2010 | 648 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 4.79 Billion USD | 0.69% |
| 2024 Q3 | 5.04 Billion USD | -2.5% |
| 2024 Q2 | 5.17 Billion USD | 7.82% |
| 2023 Q2 | 5.03 Billion USD | 8.5% |
| 2023 Q1 | 4.63 Billion USD | 2.75% |
| 2023 Q4 | 4.76 Billion USD | -4.65% |
| 2023 Q3 | 4.99 Billion USD | -0.74% |
| 2023 FY | 4.76 Billion USD | 5.52% |
| 2022 Q2 | 4.08 Billion USD | 13.47% |
| 2022 FY | 4.51 Billion USD | 38.39% |
| 2022 Q4 | 4.51 Billion USD | 6.29% |
| 2022 Q3 | 4.24 Billion USD | 3.92% |
| 2022 Q1 | 3.6 Billion USD | 10.43% |
| 2021 FY | 3.26 Billion USD | -13.27% |
| 2021 Q4 | 3.26 Billion USD | -6.24% |
| 2021 Q3 | 3.47 Billion USD | -5.62% |
| 2021 Q2 | 3.68 Billion USD | -1.68% |
| 2021 Q1 | 3.74 Billion USD | -0.32% |
| 2020 Q3 | 4.2 Billion USD | -6.4% |
| 2020 Q2 | 4.49 Billion USD | -3.73% |
| 2020 Q4 | 3.76 Billion USD | -10.67% |
| 2020 FY | 3.76 Billion USD | -19.64% |
| 2020 Q1 | 4.67 Billion USD | -0.17% |
| 2019 Q3 | 4.8 Billion USD | -1.21% |
| 2019 FY | 4.67 Billion USD | -3.53% |
| 2019 Q4 | 4.67 Billion USD | -2.62% |
| 2019 Q1 | 4.85 Billion USD | 0.0% |
| 2019 Q2 | 4.86 Billion USD | 0.29% |
| 2018 Q3 | 5.15 Billion USD | 51.75% |
| 2018 Q4 | 4.85 Billion USD | -5.92% |
| 2018 FY | 4.85 Billion USD | 43.11% |
| 2018 Q2 | 3.39 Billion USD | 2.94% |
| 2018 Q1 | 3.3 Billion USD | -2.63% |
| 2017 Q3 | 3.72 Billion USD | -3.7% |
| 2017 Q1 | 3.83 Billion USD | 2.62% |
| 2017 FY | 3.38 Billion USD | -9.41% |
| 2017 Q4 | 3.38 Billion USD | -8.92% |
| 2017 Q2 | 3.86 Billion USD | 0.65% |
| 2016 Q2 | 3.81 Billion USD | 0.47% |
| 2016 Q3 | 3.81 Billion USD | 0.13% |
| 2016 Q4 | 3.74 Billion USD | -1.97% |
| 2016 FY | 3.74 Billion USD | 0.73% |
| 2016 Q1 | 3.79 Billion USD | 2.13% |
| 2015 Q3 | 3.04 Billion USD | -1.97% |
| 2015 FY | 3.71 Billion USD | 34.18% |
| 2015 Q4 | 3.71 Billion USD | 22.09% |
| 2015 Q2 | 3.1 Billion USD | 0.55% |
| 2015 Q1 | 3.08 Billion USD | 11.49% |
| 2014 Q3 | 3.05 Billion USD | -0.72% |
| 2014 Q4 | 2.76 Billion USD | -9.36% |
| 2014 FY | 2.76 Billion USD | -9.16% |
| 2014 Q1 | 3.15 Billion USD | 3.45% |
| 2014 Q2 | 3.07 Billion USD | -2.41% |
| 2013 Q2 | 3.28 Billion USD | 3.3% |
| 2013 Q3 | 3.26 Billion USD | -0.61% |
| 2013 Q1 | 3.17 Billion USD | 1099.25% |
| 2013 FY | 3.04 Billion USD | 1049.81% |
| 2013 Q4 | 3.04 Billion USD | -6.62% |
| 2012 FY | 265 Million USD | -46.57% |
| 2012 Q1 | 466 Million USD | -6.05% |
| 2012 Q2 | 467 Million USD | 0.21% |
| 2012 Q3 | 447 Million USD | -4.28% |
| 2012 Q4 | 265 Million USD | -40.72% |
| 2011 Q4 | 496 Million USD | 0.0% |
| 2011 FY | 496 Million USD | -23.46% |
| 2010 FY | 648 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 2.65 Billion USD | -79.091% |
| Bausch Health Companies Inc. | 21.44 Billion USD | 77.79% |
| Catalent, Inc. | 4.69 Billion USD | -1.341% |
| Emergent BioSolutions Inc. | 765.8 Million USD | -521.833% |
| Elanco Animal Health Incorporated | 5.42 Billion USD | 12.173% |
| Perrigo Company plc | 3.32 Billion USD | -43.343% |
| Teva Pharmaceutical Industries Limited | 16.92 Billion USD | 71.867% |